Live SpaceX Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow MEI Pharma, Inc.

Get SEC filing alerts via email and in your feed for MEI Pharma, Inc.

MEIP

MEI Pharma, Inc.

About MEI Pharma, Inc.

Lite Strategy, Inc. is a pharmaceutical company focused on developing innovative cancer therapies. Its pipeline includes oral inhibitors targeting key oncogenic pathways, with a focus on combination treatments to overcome resistance. The company engages in clinical development, strategic partnerships, licensing, and out-licensing, operating in competitive global markets. It emphasizes intellectual property protection and regulatory compliance to bring targeted oncology drugs to patients.
This description was generated via AI from an annual report. Updated 9 months ago.

Latest SEC Filings from MEI Pharma, Inc.

1
1
MEI Pharma, Inc. Lite Strategy, Inc. Reports $23.7 Million Net Loss and Shift to Digital Asset Management

Via official filing (AI summary) | about 1 month ago | 0 comments

2
1
MEI Pharma, Inc. Lite Strategy, Inc. Reports $30.8 Million Net Loss and Strategic Shift Towards Digital Assets

Via official filing (AI summary) | 4 months ago | 0 comments

3
1
MEI Pharma, Inc. Lite Strategy, Inc. Reports $3.6 Million Net Loss and $100 Million PIPE Transaction

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
MEI Pharma, Inc. Lite Strategy, Inc. Reports No Revenue and $15.9 Million Net Loss for Fiscal Year Ending June 30, 2025

Via official filing (AI summary) | 9 months ago | 0 comments

5
1
MEI Pharma, Inc. MEI Pharma Reports No Revenue and $2.6 Million Net Loss in Latest Quarter

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
MEI Pharma, Inc. MEI Pharma Reports No Revenue and Strategic Shift Amid Financial Challenges

Via official filing (AI summary) | over 1 year ago | 0 comments

7
1
MEI Pharma, Inc. MEI Pharma Reports Significant Financial Challenges, Net Loss, and Halted Clinical Trials in Q3 2024

Via official filing (AI summary) | over 1 year ago | 0 comments